RecruitingNot ApplicableNCT05540262

Edaravone in the Treatment of Optic Neuritis

Sponsor

First Affiliated Hospital of Guangxi Medical University

Enrollment

50 participants

Start Date

Jan 15, 2022

Study Type

INTERVENTIONAL

Conditions

Optic Neuritis

Summary

Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria3

Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis
Patients with a first episode of optic neuritis in either eye
First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone

Exclusion Criteria2

Myopia over 6 diopters
Refractive media opacity affecting assessment of retinal layers and/or visual acuity

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEdaravone

Edaravone injection 30mg three times a day

Locations(1)

Yi Du

Nanning, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05540262

Related Trials

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

NCT025213111 location

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

NCT0710099024 locations